causal

Regulatory Arbitrage Steers Investment Toward Cancer and Rare Disease

Because cancers and rare genetic diseases have high unmet need and lower evidence requirements for accelerated approval, companies invest disproportionately there, bypassing large Phase III trials that are needed in conditions with established standards of care like diabetes.

causalpending

Speaker

Alex

Evidence Quote

“you've seen a lot of this investment in cancers and rare genetic diseases. The requirement for evidence is lower and the need is greater.”

Source

Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the Best
Created: 11/14/2026, 6:42:06 AM

Your notes

Loading notes...